Loading…
Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience
Introduction The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use. Methods Between 2011 and 2013, 38 patients fr...
Saved in:
Published in: | Clinical transplantation 2022-05, Vol.36 (5), p.e14591-n/a |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3 |
container_end_page | n/a |
container_issue | 5 |
container_start_page | e14591 |
container_title | Clinical transplantation |
container_volume | 36 |
creator | Chen, Qiudong Singer‐Englar, Tahli Kobashigawa, Jon A. Roach, Amy Emerson, Dominic Megna, Dominick Ramzy, Danny Catarino, Pedro Patel, Jignesh K. Kittleson, Michelle Czer, Lawrence Chikwe, Joanna Esmailian, Fardad |
description | Introduction
The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use.
Methods
Between 2011 and 2013, 38 patients from a single center were randomized as a part of the PROCEED II trial to receive allografts preserved with CS (n = 19) or OCS (n = 19). Endpoints included 8‐year survival, survival free from graft‐related deaths, freedom from cardiac allograft vasculopathy (CAV), non‐fatal major adverse cardiac events (NF‐MACE), and rejections.
Results
Eight‐year survival was 57.9% in the OCS group and 73.7% in the CS group (p = .24). Freedom from CAV was 89.5% in the OCS group and 67.8% in the CS group (p = .13). Freedom from NF‐MACE was 89.5% in the OCS group and 67.5% in the CS group (p = .14). Eight‐year survival free from graft‐related death was equivalent between the two groups (84.2% vs. 84.2%, p = .93). No differences in rejection episodes were observed (all p > .5).
Conclusions
In select patients receiving OCS preserved allografts, late post‐transplant survival trended lower than those transplanted with an allograft preserved with CS. This is based on a small single‐center series, and larger numbers are needed to confirm these findings. |
doi_str_mv | 10.1111/ctr.14591 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11144456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2620081162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3</originalsourceid><addsrcrecordid>eNp1kb9OHDEQxq0oKBwkRV4AuQzFgWe9f27TROgEAemkSBGpLa89Phx27YvtPaCjpOQZeZL4OIKSIm7s8fzmm9F8hHwEdgT5HKsUjqCsWnhDJsDbdsoYFG_JhLWsyO-a75K9GH_m3xrq6h3Z5RXjrGhmE_Kw8G75dP-YMAzUj0n5ASOVJsf0CmVINAXp4qqXLslkvaNjtG5J8Zau7dpT2fd-GTJPVxhMzmXCOhqTdFoGTYON11R750P8TE_oprbH3E-h27TA21xm0Sl8T3aM7CN-eLn3yY-z08v5-XTx7evF_GQxVWWefmpYpxtoK9PhTDI0JaA2qEBxANnpipfQNLxmlS6KTgKXpmw7jZqZmjWaKb5Pvmx1V2M3oN7MEWQvVsEOMtwJL634N-PslVj6tciLLsuyqrPCpxeF4H-NGJMYbFTY5xWhH6Mo6oKxGUBdZPRwi6rgYwxoXvsA2wiCyNaJZ-sye_D3YK_kH68ycLwFbmyPd_9XEvPL71vJ30nhqjA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2620081162</pqid></control><display><type>article</type><title>Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience</title><source>Wiley</source><creator>Chen, Qiudong ; Singer‐Englar, Tahli ; Kobashigawa, Jon A. ; Roach, Amy ; Emerson, Dominic ; Megna, Dominick ; Ramzy, Danny ; Catarino, Pedro ; Patel, Jignesh K. ; Kittleson, Michelle ; Czer, Lawrence ; Chikwe, Joanna ; Esmailian, Fardad</creator><creatorcontrib>Chen, Qiudong ; Singer‐Englar, Tahli ; Kobashigawa, Jon A. ; Roach, Amy ; Emerson, Dominic ; Megna, Dominick ; Ramzy, Danny ; Catarino, Pedro ; Patel, Jignesh K. ; Kittleson, Michelle ; Czer, Lawrence ; Chikwe, Joanna ; Esmailian, Fardad</creatorcontrib><description>Introduction
The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use.
Methods
Between 2011 and 2013, 38 patients from a single center were randomized as a part of the PROCEED II trial to receive allografts preserved with CS (n = 19) or OCS (n = 19). Endpoints included 8‐year survival, survival free from graft‐related deaths, freedom from cardiac allograft vasculopathy (CAV), non‐fatal major adverse cardiac events (NF‐MACE), and rejections.
Results
Eight‐year survival was 57.9% in the OCS group and 73.7% in the CS group (p = .24). Freedom from CAV was 89.5% in the OCS group and 67.8% in the CS group (p = .13). Freedom from NF‐MACE was 89.5% in the OCS group and 67.5% in the CS group (p = .14). Eight‐year survival free from graft‐related death was equivalent between the two groups (84.2% vs. 84.2%, p = .93). No differences in rejection episodes were observed (all p > .5).
Conclusions
In select patients receiving OCS preserved allografts, late post‐transplant survival trended lower than those transplanted with an allograft preserved with CS. This is based on a small single‐center series, and larger numbers are needed to confirm these findings.</description><identifier>ISSN: 0902-0063</identifier><identifier>EISSN: 1399-0012</identifier><identifier>DOI: 10.1111/ctr.14591</identifier><identifier>PMID: 35030278</identifier><language>eng</language><publisher>Denmark</publisher><subject>Allografts ; heart (allograft) function/dysfunction ; heart disease ; Heart Diseases ; Heart Transplantation - adverse effects ; Humans ; organ perfusion and preservation ; Organ Preservation ; patient survival ; Perfusion ; Tissue Donors</subject><ispartof>Clinical transplantation, 2022-05, Vol.36 (5), p.e14591-n/a</ispartof><rights>2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3</citedby><cites>FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3</cites><orcidid>0000-0002-2475-4312 ; 0000-0001-9308-3172 ; 0000-0003-4492-2691 ; 0000-0002-1445-6610 ; 0000-0001-5728-0152 ; 0000-0002-8169-0781 ; 0000-0002-6154-1199 ; 0000-0001-5744-2625 ; 0000-0002-7328-5903</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35030278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Qiudong</creatorcontrib><creatorcontrib>Singer‐Englar, Tahli</creatorcontrib><creatorcontrib>Kobashigawa, Jon A.</creatorcontrib><creatorcontrib>Roach, Amy</creatorcontrib><creatorcontrib>Emerson, Dominic</creatorcontrib><creatorcontrib>Megna, Dominick</creatorcontrib><creatorcontrib>Ramzy, Danny</creatorcontrib><creatorcontrib>Catarino, Pedro</creatorcontrib><creatorcontrib>Patel, Jignesh K.</creatorcontrib><creatorcontrib>Kittleson, Michelle</creatorcontrib><creatorcontrib>Czer, Lawrence</creatorcontrib><creatorcontrib>Chikwe, Joanna</creatorcontrib><creatorcontrib>Esmailian, Fardad</creatorcontrib><title>Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience</title><title>Clinical transplantation</title><addtitle>Clin Transplant</addtitle><description>Introduction
The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use.
Methods
Between 2011 and 2013, 38 patients from a single center were randomized as a part of the PROCEED II trial to receive allografts preserved with CS (n = 19) or OCS (n = 19). Endpoints included 8‐year survival, survival free from graft‐related deaths, freedom from cardiac allograft vasculopathy (CAV), non‐fatal major adverse cardiac events (NF‐MACE), and rejections.
Results
Eight‐year survival was 57.9% in the OCS group and 73.7% in the CS group (p = .24). Freedom from CAV was 89.5% in the OCS group and 67.8% in the CS group (p = .13). Freedom from NF‐MACE was 89.5% in the OCS group and 67.5% in the CS group (p = .14). Eight‐year survival free from graft‐related death was equivalent between the two groups (84.2% vs. 84.2%, p = .93). No differences in rejection episodes were observed (all p > .5).
Conclusions
In select patients receiving OCS preserved allografts, late post‐transplant survival trended lower than those transplanted with an allograft preserved with CS. This is based on a small single‐center series, and larger numbers are needed to confirm these findings.</description><subject>Allografts</subject><subject>heart (allograft) function/dysfunction</subject><subject>heart disease</subject><subject>Heart Diseases</subject><subject>Heart Transplantation - adverse effects</subject><subject>Humans</subject><subject>organ perfusion and preservation</subject><subject>Organ Preservation</subject><subject>patient survival</subject><subject>Perfusion</subject><subject>Tissue Donors</subject><issn>0902-0063</issn><issn>1399-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kb9OHDEQxq0oKBwkRV4AuQzFgWe9f27TROgEAemkSBGpLa89Phx27YvtPaCjpOQZeZL4OIKSIm7s8fzmm9F8hHwEdgT5HKsUjqCsWnhDJsDbdsoYFG_JhLWsyO-a75K9GH_m3xrq6h3Z5RXjrGhmE_Kw8G75dP-YMAzUj0n5ASOVJsf0CmVINAXp4qqXLslkvaNjtG5J8Zau7dpT2fd-GTJPVxhMzmXCOhqTdFoGTYON11R750P8TE_oprbH3E-h27TA21xm0Sl8T3aM7CN-eLn3yY-z08v5-XTx7evF_GQxVWWefmpYpxtoK9PhTDI0JaA2qEBxANnpipfQNLxmlS6KTgKXpmw7jZqZmjWaKb5Pvmx1V2M3oN7MEWQvVsEOMtwJL634N-PslVj6tciLLsuyqrPCpxeF4H-NGJMYbFTY5xWhH6Mo6oKxGUBdZPRwi6rgYwxoXvsA2wiCyNaJZ-sye_D3YK_kH68ycLwFbmyPd_9XEvPL71vJ30nhqjA</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Chen, Qiudong</creator><creator>Singer‐Englar, Tahli</creator><creator>Kobashigawa, Jon A.</creator><creator>Roach, Amy</creator><creator>Emerson, Dominic</creator><creator>Megna, Dominick</creator><creator>Ramzy, Danny</creator><creator>Catarino, Pedro</creator><creator>Patel, Jignesh K.</creator><creator>Kittleson, Michelle</creator><creator>Czer, Lawrence</creator><creator>Chikwe, Joanna</creator><creator>Esmailian, Fardad</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2475-4312</orcidid><orcidid>https://orcid.org/0000-0001-9308-3172</orcidid><orcidid>https://orcid.org/0000-0003-4492-2691</orcidid><orcidid>https://orcid.org/0000-0002-1445-6610</orcidid><orcidid>https://orcid.org/0000-0001-5728-0152</orcidid><orcidid>https://orcid.org/0000-0002-8169-0781</orcidid><orcidid>https://orcid.org/0000-0002-6154-1199</orcidid><orcidid>https://orcid.org/0000-0001-5744-2625</orcidid><orcidid>https://orcid.org/0000-0002-7328-5903</orcidid></search><sort><creationdate>202205</creationdate><title>Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience</title><author>Chen, Qiudong ; Singer‐Englar, Tahli ; Kobashigawa, Jon A. ; Roach, Amy ; Emerson, Dominic ; Megna, Dominick ; Ramzy, Danny ; Catarino, Pedro ; Patel, Jignesh K. ; Kittleson, Michelle ; Czer, Lawrence ; Chikwe, Joanna ; Esmailian, Fardad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Allografts</topic><topic>heart (allograft) function/dysfunction</topic><topic>heart disease</topic><topic>Heart Diseases</topic><topic>Heart Transplantation - adverse effects</topic><topic>Humans</topic><topic>organ perfusion and preservation</topic><topic>Organ Preservation</topic><topic>patient survival</topic><topic>Perfusion</topic><topic>Tissue Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Qiudong</creatorcontrib><creatorcontrib>Singer‐Englar, Tahli</creatorcontrib><creatorcontrib>Kobashigawa, Jon A.</creatorcontrib><creatorcontrib>Roach, Amy</creatorcontrib><creatorcontrib>Emerson, Dominic</creatorcontrib><creatorcontrib>Megna, Dominick</creatorcontrib><creatorcontrib>Ramzy, Danny</creatorcontrib><creatorcontrib>Catarino, Pedro</creatorcontrib><creatorcontrib>Patel, Jignesh K.</creatorcontrib><creatorcontrib>Kittleson, Michelle</creatorcontrib><creatorcontrib>Czer, Lawrence</creatorcontrib><creatorcontrib>Chikwe, Joanna</creatorcontrib><creatorcontrib>Esmailian, Fardad</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Qiudong</au><au>Singer‐Englar, Tahli</au><au>Kobashigawa, Jon A.</au><au>Roach, Amy</au><au>Emerson, Dominic</au><au>Megna, Dominick</au><au>Ramzy, Danny</au><au>Catarino, Pedro</au><au>Patel, Jignesh K.</au><au>Kittleson, Michelle</au><au>Czer, Lawrence</au><au>Chikwe, Joanna</au><au>Esmailian, Fardad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience</atitle><jtitle>Clinical transplantation</jtitle><addtitle>Clin Transplant</addtitle><date>2022-05</date><risdate>2022</risdate><volume>36</volume><issue>5</issue><spage>e14591</spage><epage>n/a</epage><pages>e14591-n/a</pages><issn>0902-0063</issn><eissn>1399-0012</eissn><abstract>Introduction
The Organ Care System (OCS) is an ex vivo perfusion platform for donor heart preservation. Short/mid‐term post‐transplant outcomes after its use are comparable to standard cold storage (CS). We evaluated long‐term outcomes following its use.
Methods
Between 2011 and 2013, 38 patients from a single center were randomized as a part of the PROCEED II trial to receive allografts preserved with CS (n = 19) or OCS (n = 19). Endpoints included 8‐year survival, survival free from graft‐related deaths, freedom from cardiac allograft vasculopathy (CAV), non‐fatal major adverse cardiac events (NF‐MACE), and rejections.
Results
Eight‐year survival was 57.9% in the OCS group and 73.7% in the CS group (p = .24). Freedom from CAV was 89.5% in the OCS group and 67.8% in the CS group (p = .13). Freedom from NF‐MACE was 89.5% in the OCS group and 67.5% in the CS group (p = .14). Eight‐year survival free from graft‐related death was equivalent between the two groups (84.2% vs. 84.2%, p = .93). No differences in rejection episodes were observed (all p > .5).
Conclusions
In select patients receiving OCS preserved allografts, late post‐transplant survival trended lower than those transplanted with an allograft preserved with CS. This is based on a small single‐center series, and larger numbers are needed to confirm these findings.</abstract><cop>Denmark</cop><pmid>35030278</pmid><doi>10.1111/ctr.14591</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2475-4312</orcidid><orcidid>https://orcid.org/0000-0001-9308-3172</orcidid><orcidid>https://orcid.org/0000-0003-4492-2691</orcidid><orcidid>https://orcid.org/0000-0002-1445-6610</orcidid><orcidid>https://orcid.org/0000-0001-5728-0152</orcidid><orcidid>https://orcid.org/0000-0002-8169-0781</orcidid><orcidid>https://orcid.org/0000-0002-6154-1199</orcidid><orcidid>https://orcid.org/0000-0001-5744-2625</orcidid><orcidid>https://orcid.org/0000-0002-7328-5903</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0902-0063 |
ispartof | Clinical transplantation, 2022-05, Vol.36 (5), p.e14591-n/a |
issn | 0902-0063 1399-0012 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11144456 |
source | Wiley |
subjects | Allografts heart (allograft) function/dysfunction heart disease Heart Diseases Heart Transplantation - adverse effects Humans organ perfusion and preservation Organ Preservation patient survival Perfusion Tissue Donors |
title | Long‐term outcomes after heart transplantation using ex vivo allograft perfusion in standard risk donors: A single‐center experience |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T05%3A28%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%E2%80%90term%20outcomes%20after%20heart%20transplantation%20using%20ex%20vivo%20allograft%20perfusion%20in%20standard%20risk%20donors:%20A%20single%E2%80%90center%20experience&rft.jtitle=Clinical%20transplantation&rft.au=Chen,%20Qiudong&rft.date=2022-05&rft.volume=36&rft.issue=5&rft.spage=e14591&rft.epage=n/a&rft.pages=e14591-n/a&rft.issn=0902-0063&rft.eissn=1399-0012&rft_id=info:doi/10.1111/ctr.14591&rft_dat=%3Cproquest_pubme%3E2620081162%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4161-f0bd7195fbe8a0ef41edfec1c311abd5341773605d22ba13af49bded0f607d0c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2620081162&rft_id=info:pmid/35030278&rfr_iscdi=true |